ArticleFrontiers in pharmacology2026
Coenzyme Q10 alleviates silicotic fibrosis in rats through the TGF-β1/Smad pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silicosis, the most prevalent occupational disease worldwide, currently lacks effective clinical treatments. Therefore, identifying an effective intervention and preventive drug is crucial for inhibiting silicosis fibrosis. Our preliminary experiments suggested that coenzyme Q10 (CoQ10) may alleviate fibrosis in a rat silicosis model, but the underlying mechanism remains unclear. Methods: In this study, a rat silicosis model was established via a single tracheal instillation of SiO Results: Results showed that CoQ10 significantly reduced levels of inflammatory cytokines IL-1β and TNF-α in bronchoalveolar lavage fluid (BALF), alleviated lung tissue inflammation, oxidative stress, and collagen deposition. In the medium- and high-dose CoQ10 groups, expression of fibrosis-related proteins (α-SMA, Vimentin, Col-I, Col-III) decreased, while E-cad expression increased. Moreover, expression of TGF-β1, Smad2, and Smad3 was downregulated, and Smad7 expression was upregulated. Conclusion: These findings suggest that the anti-fibrotic effect of CoQ10 on silicosis may be associated with reducing pulmonary inflammation and oxidative stress, thereby inhibiting the TGF-β1/Smad signaling pathway. This study provides new insights into understanding the pathogenesis and potential treatment of silicosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.